Cystic Fibrosis: Red-Flag Clinical Symptoms, Modern Therapeutic Modalities, and Comprehensive Nutritional Protocols

Cystic fibrosis stems from deleterious mutations within the CFTR gene mapped to chromosome 7q31.2. The F508del mutation—an in-frame trinucleotide deletion causing loss of phenylalanine at codon 508—accounts for roughly 70% of mutant alleles globally. Defective CFTR channels arrest apical chloride and bicarbonate extrusion while triggering constitutive hyperabsorption of sodium and water via ENaC channels, precipitating mucosal dehydration.

Hallmark clinical presentations include:

• Neonatal period: Meconium ileus presenting in 15–20% of affected neonates, protracted cholestatic jaundice.
• Pulmonary symptoms: Recurrent intractable wet cough, chronic purulent bronchitis, progressive bronchiectasis, nasal polyposis.
• Gastrointestinal symptoms: Exocrine pancreatic insufficiency (85–90% of cohorts), voluminous foul-smelling steatorrhea, failure to thrive despite ravenous appetite.
• Diagnostic criteria: Newborn screening via immunoreactive trypsinogen (IRT), quantitative pilocarpine iontophoresis sweat test (sweat chloride >60 mmol/L), and targeted CFTR mutation sequencing.

Contemporary cystic fibrosis management has undergone a paradigm shift following the clinical advent of CFTR modulators (notably the triple combination regimen: elexacaftor/tezacaftor/ivacaftor). These small molecules address root molecular pathology by correcting polypeptide misfolding and potentiating channel gating at the apical plasma membrane.

Supportive care remains foundational: daily respiratory clearance techniques (autogenic drainage, high-frequency chest wall oscillation), inhalation of recombinant human dornase alfa and hypertonic saline to cleave viscoelastic neutrophil DNA, and inhaled antimicrobial suppression of chronic Pseudomonas aeruginosa colonization.

Nutritional status directly dictates pulmonary function (FEV1) and median survival:

• Caloric density: Prescribed caloric intake ranges from 120% to 150% (up to 200% during pulmonary exacerbations) of age-matched healthy populations, emphasizing high fat (35–45% total calories) and high protein.
• Pancreatic Enzyme Replacement Therapy (PERT): Enteric-coated pancrelipase microtablets administered immediately preceding all fat- and protein-containing intake.
• Fat-soluble vitamins: Daily high-dose water-miscible ADEK formulations to counteract profound malabsorption.
• Sodium supplementation: Obligate sodium chloride supplementation to prevent hypochloremic hyponatremic dehydration during heat stress.